0000943535 false --12-31 Q1 000-30256 0000943535 2022-01-01 2022-03-31 0000943535 2022-05-11 0000943535 2022-03-31 0000943535 2021-12-31 0000943535 WHEN:SeriesBConvertiblePreferredStockMember 2022-03-31 0000943535 WHEN:SeriesBConvertiblePreferredStockMember 2021-12-31 0000943535 2021-01-01 2021-03-31 0000943535 us-gaap:PreferredStockMember 2021-12-31 0000943535 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0000943535 us-gaap:CommonStockMember 2021-12-31 0000943535 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000943535 WHEN:ProceedsOnAccountOfSharesMember 2021-12-31 0000943535 WHEN:ForeignCurrencyTranslationAdjustmentsMember 2021-12-31 0000943535 us-gaap:RetainedEarningsMember 2021-12-31 0000943535 us-gaap:PreferredStockMember 2020-12-31 0000943535 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-12-31 0000943535 us-gaap:CommonStockMember 2020-12-31 0000943535 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000943535 WHEN:ForeignCurrencyTranslationAdjustmentsMember 2020-12-31 0000943535 us-gaap:RetainedEarningsMember 2020-12-31 0000943535 2020-12-31 0000943535 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000943535 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0000943535 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000943535 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000943535 WHEN:ProceedsOnAccountOfSharesMember 2022-01-01 2022-03-31 0000943535 WHEN:ForeignCurrencyTranslationAdjustmentsMember 2022-01-01 2022-03-31 0000943535 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000943535 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000943535 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0000943535 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000943535 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000943535 WHEN:ForeignCurrencyTranslationAdjustmentsMember 2021-01-01 2021-03-31 0000943535 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000943535 us-gaap:PreferredStockMember 2022-03-31 0000943535 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-03-31 0000943535 us-gaap:CommonStockMember 2022-03-31 0000943535 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000943535 WHEN:ProceedsOnAccountOfSharesMember 2022-03-31 0000943535 WHEN:ForeignCurrencyTranslationAdjustmentsMember 2022-03-31 0000943535 us-gaap:RetainedEarningsMember 2022-03-31 0000943535 us-gaap:PreferredStockMember 2021-03-31 0000943535 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-03-31 0000943535 us-gaap:CommonStockMember 2021-03-31 0000943535 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000943535 WHEN:ForeignCurrencyTranslationAdjustmentsMember 2021-03-31 0000943535 us-gaap:RetainedEarningsMember 2021-03-31 0000943535 2021-03-31 0000943535 WHEN:CrossMobileInvestmentAgreementMember WHEN:GioraRosenzweigMember 2022-03-22 0000943535 WHEN:CrossMobileInvestmentAgreementMember WHEN:GeorgeBaumoehlMember 2022-03-22 0000943535 us-gaap:CommonStockMember WHEN:CrossMobileInvestmentAgreementMember 2022-03-21 2022-03-22 0000943535 us-gaap:CommonStockMember WHEN:CrossMobileInvestmentAgreementMember 2022-03-22 0000943535 WHEN:CrossMobileInvestmentAgreementMember 2022-03-21 2022-03-22 0000943535 WHEN:PrivatePlacementTwoThousandTwentyOneMember WHEN:SubscriptionAgreementsMember 2021-10-31 0000943535 WHEN:PrivatePlacementTwoThousandTwentyOneMember WHEN:SubscriptionAgreementsMember 2022-01-01 2022-03-31 0000943535 us-gaap:CommonStockMember WHEN:SubscriptionAgreementsMember WHEN:PrivatePlacementTwoThousandTwentyOneMember 2022-01-01 2022-03-31 0000943535 us-gaap:PrivatePlacementMember WHEN:SubscriptionAgreementsMember 2022-01-01 2022-03-31 0000943535 us-gaap:PrivatePlacementMember WHEN:SubscriptionAgreementsMember 2022-03-31 0000943535 us-gaap:CommonStockMember WHEN:SubscriptionAgreementsMember us-gaap:PrivatePlacementMember 2022-01-01 2022-03-31 0000943535 WHEN:CrossMobileInvestmentAgreementMember WHEN:HenrykTomaszTromerMember 2022-02-13 2022-02-14 0000943535 WHEN:CrossMobileInvestmentAgreementMember WHEN:HenrykTomaszTromerMember 2022-02-14 0000943535 WHEN:CrossMobileInvestmentAgreementMember WHEN:HenrykTomaszTromerMember WHEN:FirstAnniversaryMember 2022-02-13 2022-02-14 0000943535 WHEN:CrossMobileInvestmentAgreementMember WHEN:HenrykTomaszTromerMember WHEN:FirstAnniversaryMember 2022-02-14 0000943535 2022-01-01 2022-01-02 0000943535 srt:MinimumMember 2022-01-01 2022-03-31 0000943535 srt:MaximumMember 2022-01-01 2022-03-31 0000943535 WHEN:ExercisePriceRangeOneMember 2022-01-01 2022-03-31 0000943535 WHEN:ExercisePriceRangeOneMember 2022-03-31 0000943535 WHEN:ExercisePriceRangeOneMember 2021-01-01 2021-12-31 0000943535 WHEN:ExercisePriceRangeOneMember 2021-12-31 0000943535 2021-01-01 2021-12-31 0000943535 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0000943535 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0000943535 WHEN:ShareBasedCompensationsMember 2022-01-01 2022-03-31 0000943535 WHEN:ShareBasedCompensationsMember 2021-01-01 2021-03-31 0000943535 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0000943535 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0000943535 us-gaap:SubsequentEventMember WHEN:TwoThousandTwentyOnePlanMember WHEN:DirectorsEmployeesAndServiceProvidersMember 2022-05-14 2022-05-15 0000943535 us-gaap:SubsequentEventMember WHEN:TwoThousandTwentyOnePlanMember WHEN:DirectorsEmployeesAndServiceProvidersMember 2022-05-15 0000943535 us-gaap:SubsequentEventMember WHEN:TwoThousandTwentyOnePlanMember srt:ChiefExecutiveOfficerMember 2022-05-14 2022-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

MARK ONE

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the Quarterly Period ended March 31 2022; or

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the transition period from ________ to ________

 

WORLD HEALTH ENERGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   59-2762023
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

1825 NW Corporate Blvd. Suite 110, Boca Raton, FL   33431
(Address of principal executive offices)   Zip Code

 

(561) 870-0440

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
      Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of May 11, 2022, 491,339,407,996 shares of the registrant’s common stock, par value $0.00001 per share, were outstanding.

 

 

 

 
 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

Form 10-Q

March 31, 2022

 

  Page
   
PART I — FINANCIAL INFORMATION  
   
Item 1 – Financial Statements – Unaudited  
   
Condensed Consolidated Balance Sheets – March 31, 2022 and December 31, 2021 3
   
Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 4
   
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three months ended March 31, 2022 and 2021 5
   
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 6
   
Notes to Condensed Consolidated Financial Statements 7
   
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations 13
   
Item 3 – Quantitative and Qualitative Disclosures About Market Risk 17
   
Item 4 – Controls and Procedures 17
   
Item 1 – Legal Proceedings 18
   
Item 1A – Risk Factors 18
   
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 19
   
Item 3 – Defaults upon Senior Securities 19
   
Item 4 – Mine Safety Disclosures 19
   
Item 5 – Other Information 19
   
Item 6 – Exhibits 19
   
Exhibit Index 19
   
SIGNATURES 20

 

i
 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF MARCH 31, 2022

IN U.S. DOLLARS

 

TABLE OF CONTENTS

 

  Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:  
Condensed Consolidated Balance sheets as of March 31, 2022 (unaudited),and December 31, 2021 3
Condensed Consolidated Statements of Comprehensive Loss for three months ended March 31, 2022 and 2021 (unaudited) 4
Condensed Consolidated Statements of stockholders’ deficit for the period of three months ended March 31, 2022 and 2021 (unaudited) 5
Condensed Consolidated Statements of cash flows for the three months ended March 31, 2022 and 2021 (unaudited) 6
Notes to unaudited condensed consolidated financial statements 7 - 12

 

2

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars except share and per share data)

 

   March 31,   December 31, 
   2022   2021 
   (Unaudited)      
Assets          
Current Assets          
Cash and cash equivalents   385,957    46,022 
Accounts receivable, net   15,774    10,022 
Prepaid share based payment to service providers   1,072,038    1,188,291 
Other current assets   78,099    67,840 
Total Current assets   1,551,868    1,312,175 
           
Right Of Use asset arising from operating lease   188,923    201,518 
Long term prepaid expenses   25,189    25,723 
Property and Equipment, Net   27,674    27,777 
Funds in respect of employee rights upon termination   22,140    21,182 
           
Total assets   1,815,794    1,588,375 
           
Liabilities and Shareholders’ Deficit          
Current Liabilities          
Accounts payable   79,690    80,059 
Right Of Use liabilities arising from operating lease   46,910    45,756 
Other account liabilities   631,998    638,388 
Total current liabilities   758,598    764,203 
           
Liability for employee rights upon retirement   159,932    157,860 
Long term loan from parent company   2,012,339    2,012,339 
Right Of Use liabilities arising from operating lease   156,736    173,227 
           
Total liabilities   3,087,605    3,107,629 
           
Stockholders’ Deficit          
Preferred stock, par $0.0007, 10,000,000 shares authorized, 5,000,000 shares issued and outstanding as of March 31, 2022 and December 31, 2021.   3,500    3,500 
Series B Convertible Preferred stock, par $0.0007, 3,870,000 shares authorized, 0 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.   -    - 
Common stock, par $0.00001, 750,000,000,000 shares authorized at March 31, 2022 and December 31, 2021. 491,339,407,996 and 488,499,407,996 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.   66,868,085    66,839,685 
Additional paid-in capital   (60,697,655)   (62,263,494)
Proceeds on account of shares   290,000    - 
Foreign currency translation adjustments   (5,495)   (5,495)
Accumulated deficit   (7,730,246)   (6,093,450)
T o t a l stockholders’ deficit   (1,271,811)   (1,519,254)
T o t a l liabilities and stockholders’ deficit   1,815,794    1,588,375 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

3

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars except share and per share data)

 

           
   Three months ended 
   March 31 
   2022   2021 
   (Unaudited) 
         
Revenues   32,542    32,649 
           
Research and development expenses   (123,506)   (172,771)
General and administrative expenses   (1,549,128)   (124,485)
Operating loss   (1,640,092)   (264,607)
Financing income (expenses), net   3,296    (1,484)
Net loss   (1,636,796)   (266,091)
           
Comprehensive loss   (1,636,796)   (266,091)
           
Loss per share (basic and diluted)   (0.00)   (0.00)

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

4

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

(U.S. dollars, except share and per share data)

 

                                             
   Preferred Stock, $0.0007, Par Value   Preferred Stock B, $0.0007, Par Value  

Common Stock,
$0.0007, Par Value

   Additional paid-in capital  

 

Proceeds on account of shares

  

Foreign currency

translation

adjustments

   Accumulated deficit   Total Company’s
stockholders’
equity
 
   Number of Shares   Amount   Number of Shares   Amount   Number of Shares   Amount                     
BALANCE AT JANUARY 1, 2022   5,000,000    3,500    -    -    488,499,407,996    66,839,685    (62,263,494)   -    (5,495)   (6,093,450)   (1,519,254)
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2022:                                                       
Issuance of shares   -    -    -    -    2,840,000,000    28,400    255,600    -    -    -    284,000 
 Share based payment to a service providers   -    -    -    -    -    -    1,310,239    -              1,310,239 
Proceeds on account of shares   -    -    -    -    -    -    -    290,000    -    -    290,000 
Comprehensive loss for three month ended March 31, 2020   -    -    -    -    -    -    -    -    -    (1,636,796)   (1,636,796)
BALANCE AT MARCH 31, 2022 (Unaudited)   5,000,000    3,500    -    -    491,339,407,996    66,868,085    (60,697,655)   290,000    (5,495)   (7,730,246)   (1,271,811)

 

                                         
   Preferred Stock, $0.0007, Par Value   Preferred Stock B, $0.0007, Par Value  

Common Stock,
$0.0007, Par Value

   Additional paid-in capital  

Foreign currency

translation

adjustments

   Accumulated deficit   Total Company’s
stockholders’
equity
 
   Number of Shares   Amount   Number of Shares   Amount   Number of Shares   Amount                 
BALANCE AT JANUARY 1, 2021   5,000,000    3,500    3,870,000    2,709    89,789,407,996    62,852,585    (63,339,224)   (5,495)   (1,496,637)   (1,982,562)
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2021:                                                  
 Comprehensive loss for three month ended March 31, 2021   -    -    -    -    -    -    -    -    (266,091)   (266,091)
BALANCE AT MARCH 31, 2021 (Unaudited)   5,000,000    3,500    3,870,000    2,709    89,789,407,996    62,852,585    (63,339,224)   (5,495)   (1,762,728)   (2,248,653)

  

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

5

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars except)

 

           
   Three months ended 
   March 31, 
   2022   2021 
   (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss for the period   (1,636,796)   (266,091)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:          
Depreciation and amortization   1,919    4,821 
Increase in liability for employee rights upon retirement   2,072    28,514 
Share based payment to a service providers   1,426,491    - 
Operating lease ROU asset and liability, net   (2,743)   (6,521)
Decrease in accounts receivable   (5,752)   (8,274)
Decrease (increase) in other current assets   (7,993)   (4,139)
Decrease in accounts payable   (369)   (5,422)
Increase in other accounts liabilities   (6,390)   37,178 
Net cash used in operating activities   (229,561)   (219,934)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Loans granted to related parties   (1,729)   - 
Proceeds from related parties   -    3,521 
Increase in asset for employee rights upon retirement   (958)   - 
Purchase of property and equipment   (1,817)   (1,668)
Net cash provided by (used in) investing activities   (4,504)   1,853 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from stock issued for cash   284,000    - 
Proceeds on account of shares   290,000    - 
Net cash provided by financing activities   574,000    - 
           
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   339,935    (218,081)
           
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD   46,022    359,949 
           
CASH AND CASH EQUIVALENTS AT END OF PERIOD   385,957    141,868 
           
Supplemental disclosure of cash flow information:        
Non cash transactions:        
Initial recognition of operating lease right-of-use assets   -    242,906 
           
Initial recognition of operating lease liability   -    (242,906)

 

The accompanying notes are an integral part of the condensed consolidated financial statement

 

6

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 1 – GENERAL

 

A.Operations

 

World Health Energy Holdings, Inc., (the “Company” or “WHEN”), was formed on May 21, 1986, under the laws of the State of Delaware. The Company has invested in and abandoned a variety of software programs that it strove to commercialize.

 

UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (Hereinafter: “RNA”).

 

RNA is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity related products.

 

In anticipation of the transaction contemplated under the Merger Agreement, SG 77 Inc. a Delaware Corporation and a wholly-owned subsidiary of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

 

CrossMobile investment agreement

 

On March 22, 2022 the Company, CrossMobile S.P.Zoo, a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which Mr. Giora Rosenzweig, holds 40.67% and Mr. George Baumeohl holds 3.33%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company is to purchase 26% of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock (the “Initial Investment”). The acquisition is subject to the registration with the Polish Companies Registrar of the shares issuable to the Company in respect of the Initial Investment, as required under local law. Upon the registration of the Company shareholdings in CrossMobnile, the closing of the Initial Investment will be deemed to have occurred and the 10,000,000,000 Company shares of common stock will be issued to CrossMobile.

 

CrossMobile is a licensed mobile virtual network operator (“MVNO”) in Poland, providing the necessary licenses and key infrastructure in the EU. With its involvement in CrossMobile, the Company expects to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

 

In addition, for 18 months following the date of the Agreement, the Company has the option to purchase additional shares of CrossMobile, such that following such additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile.

 

Under the Agreement, upon the closing of the Initial Investment, Giora Rosenzweig, is to be appointed to the CrossMobile board of directors. The Agreement provides that either party may terminate the Agreement and the transactions is the Initial Investment has not closed by September 30, 2022.

 

The preferred share capital of CrossMobile provides certain privileges, including the right to participate in CrossMobile shareholder meetings at a rate of two votes for each preferred share and preference as to distribution of dividends at a rate equal to twice the dividends distributed to the holders of the common shares in CrossMobile.

 

7

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 1 – GENERAL (continue)

 

B.Going concern uncertainty

 

Since inception, the Group has devoted substantially all its efforts to research and development. The Group is still in its development stage and the extent of the Group’s future operating losses and the timing of becoming profitable, if ever, are uncertain. As of March 31, 2022, the Group had $385,957 of cash and cash equivalents, accumulated deficit of $7,730,246, working capital of $793,270 and net losses of $1,636,796 during the three months ended March 31, 2022.

 

The Group will need to secure additional capital in the future in order to meet its anticipated liquidity needs primarily through the sale of additional Common Stock or other equity securities and/or debt financing. Funds from these sources may not be available to the Group on acceptable terms, if at all, and the Group cannot give assurance that it will be successful in securing such additional capital (see Note 3 in respect to subscription agreements signed during 2022).

 

These conditions raise substantial doubt about the Company’s ability to continue to operate as a “going concern.” The Company’s ability to continue operating as a going concern is dependent on several factors, among them is the ability to raise sufficient additional funding.

 

The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

C.Risk factors

 

The Group face a number of risks, including uncertainties regarding finalization of the development process, demand and market acceptance of the Group’s products, the effects of technological changes, competition and the development of products by competitors. Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group’s future results. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and increased marketing efforts. As mentioned above, the Group has not yet generated significant revenues from its operations to fund its activities, and therefore the continuance of its activities as a going concern depends on the receipt of additional funding from its current stockholders and investors or from third parties.

 

D.COVID-19

 

The COVID-19 pandemic continues to create business and economic uncertainty and volatility in the global markets. Many countries around the world are experiencing further outbreaks of the pandemic, following which governments are once again imposing various restrictions. At the same time, there is a recovery trend in the volume of economic activity around the world that leads on one hand, to significant demand for certain products and services and on the other hand, disruptions to worldwide supply chain routes and some raw materials. The Group continues to take measures to ensure the health and safety of its employees, suppliers, other business partners and the communities in which it operates in order to ensure, among others, the operation level, the proper functioning of its facilities and to minimize the pandemic’s potential impact on its business. Manufacturing continues at the Group’s sites without interruptions. However, there is still a difficulty in assessing the future impacts of the pandemic on the Group’s operations, inter alia, in light of the uncertainty of its duration, the extent of its intensity and effects on global supply chains and global markets, and additional countermeasures that may be taken by governments and central banks.

 

8

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Unaudited Interim Financial Statements

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the three-months ended March 31, 2022. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2022. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.

 

Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ Alternative Reporting System, for the year ended December 31, 2022.

 

Principles of Consolidation

 

The consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.

 

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to the going concern assumptions.

 

9

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)

 

Recent Accounting Pronouncements

 

In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The guidance in ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU 2020-06 also simplify the guidance in ASC Subtopic 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The amendments in ASU 2020-06 are effective for the Company for fiscal years beginning after December 15, 2021. Early adoption is permitted. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this new guidance, but does not expect it to have a material impact on its financial statements.

 

NOTE 3 – COMMON STOCK

 

Between August and October 2021, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities (the 2021 Private Placements”) where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. Subscription agreements for an aggregate of $900,000 provide that the investors are to remit the subscription proceeds at the time of investment and in three month intervals thereafter, in each case in amounts equal to 20% of their committed amounts. During the three months ended March 31, 2022, the Company received a total of $74,000 on account of these subscription and in consideration thereof issued 340,000,000 shares of Common Stock and warrants for an additional 340,000,000 shares of Common Stock and the balance is presented as proceeds on account of shares.

 

During the three months ended March 31, 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities in an aggregated amount of $500,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. As part of the subscription agreements, CrossMobile undertook to issue the investors up to 5% of the issued and outstanding share capital of CrossMobile. During the three months ended March 31, 2022, the Company received a total of $500,000 on account of these subscription and in consideration thereof issued 2,500,000,000 shares of Common Stock and warrants for an additional 2,500,000,000 shares of Common Stock and the balance is presented as proceeds on account of shares.

 

10

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 4 - STOCK OPTIONS

 

On June 21, 2021, the board of directors of the Company approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which the Company may issue awards, from time to time, consisting of non-qualified stock options, restricted stock grants and restricted stock units. In addition, stock option awards that qualify under Section 102 of the Israeli Tax Ordinance (New Version) 1961 (the “ITO”), and/or under Section 3(i) of the ITO, may be granted.

 

Mr. Tromer, the CEO of CrossMobile, was appointed to the Company’s advisory board in February 2022. In connection with his service on the advisory board, on February 14, 2022, he was awarded options under the Company’s 2021 Equity Incentive Plan to purchase 6,000,000,000 shares of the Company’s common stock, at a per share exercise price of $0.0001 per share, which the exercise price for all grants to date to member of the Company’s advisory board. Mr. Tromer’s options vest as follows: 25% (i.e., 1,500,000,000) option shares vest on the first anniversary of the appointment to the advisory board and the balance in increments of 400,000,000 shares on each subsequent three (3) month anniversary.

 

On January 1, 2022, the Company granted options to purchase 400,000,000 shares of the Company’s Common Stock to a member of its advisory board, under the Company’s 2021 Plan. Options to purchase 100,000,000 shares of Common Stock shall vest on the first anniversary of the agreement and the remaining options shall vest quarterly, over additional 3 years

 

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate between 1.12% - 1.85%, a volatility factor between 391% - 397%, dividend yields of 0% and an expected life of 4 years and was estimated at $2,600,000.

 

The following table presents the Company’s stock option activity during the three months ended March 31, 2022:

 

   Number of Options   Weighted Average Exercise Price 
Outstanding at December 31,2021   6,800,000,000    0.001 
Granted   6,400,000,000    0.001 
Exercised   -    - 
Forfeited or expired   -    - 
Outstanding at March 31,2022   13,200,000,000    0.001 
Number of options exercisable at March 31, 2022   -    - 

 

The aggregate intrinsic value of the awards outstanding as of March 31, 2022 is zero. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.0005 as of March 31, 2022, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

 

The stock options outstanding as of March 31, 2022, have been separated into exercise prices, as follows:

 

Exercise price   Stock options outstanding  

Weighted average remaining contractual

life – years

   Stock options vested 
    As of March 31, 2022 
 0.001    13,200,000,000    3.55    - 
      13,200,000,000    3.55    - 

 

The stock options outstanding as of December 31, 2021, have been separated into exercise prices, as follows:

 

Exercise price   Stock options outstanding   Weighted average remaining contractual life – years   Stock options vested 
    As of December 31, 2021 
 0.001    6,800,000,000    3.49    - 
 0.001    6,800,000,000    3.49    - 

 

Compensation expense recorded by the Company in respect of its stock-based compensation awards for the period of three months ended March 31, 2022 was $1,310,239 and are included in General and Administrative expenses in the Statements of Operations.

 

11

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 5 – RELATED PARTIES

 

A. Transactions and balances with related parties

 

           
  

Three months ended

March 31

 
   2022   2021 
         
General and administrative expenses:          
Salaries and fees to officers   960,772    39,413 
(*) of which share based compensation   919,465    - 
           
Research and development expenses:          
Salaries and fees to officers   23,415    22,653 

 

B. Balances with related parties and officers:

 

  

As of

March 31,

   As of December 31, 
   2022   2021 
         
Other current assets   8,915    7,186 
Other accounts liabilities   120,000    120,000 
Liability for employee rights upon retirement   212,870    213,371 
Long term loan from related party   2,012,339    2,012,339 

 

NOTE 6 – SUBSEQUENT EVENTS

 

On May 15, 2022, the Company granted options under the 2021 Plan (2021) to directors, employees and service providers to purchase an aggregate of 34,900,000,000 shares of Common Stock exercisable at a per share exercise price of $0.0001. Of the options granted, 5,000,000,000 were issued to CEO. The options vest on an annual basis with 25% of the option grant vesting on each anniversary of the option grant. Following vesting the options are exercisable through the sixth month anniversary following the last instalment vesting date.

 

12

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2022. Certain statements made in this discussion are “forward-looking statements” within the meaning of the private securities litigation reform act of 1995,. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations and the effects that the COVID-19 outbreak, or similar pandemics, could have on our business. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

 

The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

 

Business Overview

 

World Health Energy Holdings, Inc. (“we” “us” “our” the “Company” or “WHEN”) WHEN is a diversified energy, health, and cybersecurity technology company. On April 27, 2020, WHEN completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) among the Company, R2GA, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Sub”), UCG, Inc., a Florida corporation (“Seller”), SG 77 Inc., a Delaware corporation and wholly-owned subsidiary of Seller (“SG”), and RNA Ltd., an Israeli company and a wholly owned subsidiary of SG (“RNA”). Under the terms of the Merger Agreement, R2GA merged with and into SG, with SG remaining as the surviving corporation and a wholly-owned subsidiary of the Company (the “Merger”). The Merger became effective as of April 29, 2020. Each of Gaya Rozensweig and George Baumeohl, directors of the Company, are also the sole shareholders and directors of UCG.

 

13
 

 

RNA is primarily a research and development company that has been performing software design services in the field of cybersecurity. SG is primarily engaged in the marketing and distribution of cybersecurity related products. In anticipation of the transaction contemplated under the Merger Agreement, SG was formed and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

 

Following the closing, each of SG 77 and RNA became wholly-owned subsidiaries of the Company.

 

Recent Developments

 

(i) On March 22, 2022 the Company, CrossMobile Sp zoo, a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which our CEO, Giora Rosenzweig, holds 40.67% and George Baumeohl, a director, holds 3.33%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company is to purchase 26% of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock (the “Initial Investment”). The acquisition is subject to the registration with the Polish Companies Registrar of the shares issuable to the Company in respect of the Initial Investment, as required under local law. Upon the registration of the Company shareholdings in CrossMobnile, the closing of the Initial Investment will be deemed to have occurred and the 10,000,000,000 Company shares of common stock will be issued to CrossMobile. In addition, for 18 months following the date of the Agreement, the Company has the option to purchase additional shares of CrossMobile, such that following such additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile.

 

Under the Agreement, upon the closing of the Initial Investment, Giora Rosenzweig, is to be appointed to the CrossMobile board of directors. The Agreement provides that either party may terminate the Agreement and the transactions is the Initial Investment has not closed by September 30, 2022.

 

The preferred share capital of CrossMobile provides certain privileges, including the right to participate in CrossMobile shareholder meetings at a rate of two votes for each preferred share and preference as to distribution of dividends at a rate equal to twice the dividends distributed to the holders of the common shares in CrossMobile.

 

We believe that the acquisition of CrossMobile provides an opportunity in our evolution and provides us with a strong foothold in the European market. CrossMobile is part of a limited group of licensed operators in the EU. CrossMobile is planning to roll-out a comprehensive suite of value-added services for B2B and B2C customers in the telecom industry.

 

With our involvement in CrossMobile, we expect to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings as well the access to the EU market for our CyberSecurity products.

 

Key Financial Terms and Metrics

 

The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements.

 

14
 

 

Revenues

 

We currently generate revenues primarily from software license fees.

 

Research and Development Expenses

 

The process of researching and developing our product candidates is lengthy, unpredictable, and subject to many risks. We expect to continue incurring substantial expenses through 2023 as we continue to develop our product offerings and adapt them to our new MVNO business. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred..

 

Our research and development costs include costs are comprised of:

 

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

 

● fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

 

Marketing

 

Marketing expenses consist primarily of salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive and other support staff. Other significant marketing expenses include the costs associated with professional fees to develop our marketing strategy.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive, administrative and other support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting, auditing, insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative functions.

 

Financial Expenses

 

Financial expenses consist primarily impact of exchange rate derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial expenses include bank’s fees and interest on long term loans.

 

Comparison of the Three Months Ended March 31, 2022 to the Three Months Ended March 31, 2021

 

The following table presents our results of operations for the three months ended March 31, 2022 and 2021

 

   Three Months Ended 
   March 31 
   2022   2021 
         
Revenues   32,542    32,649 
Operating Expenses   -    - 
Research and development expenses   (123,506)   (172,771)
General and administrative expenses   (1,549,128)   (124,485)
Operating loss   (1,640,092)   (264,607)
Financing income (expenses), net   3,296    (1,484)
Net loss   (1,636,796)   (266,091)

 

 

15
 

 

Revenues. Revenues for the three months ended March 31, 2022 and 2021 were $32,542 and $32,649, respectively. Revenues were comprised primarily of software license fees.

 

Research and Development. Research and development expenses consist of salaries and related expenses, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses decreased to $123,506 in the three months ended March 31, 2022 from $172,771 during the corresponding period in 2021. The decrease resulted primarily from salaries and related expenses.

 

General and Administrative Expenses. General and administrative expenses consist primarily of share base compensation expenses, salaries and related expenses and other non-personnel related. General and administrative expenses increased to $1,549,128 for the three months ended March 31, 2022 from $124,485 during the corresponding period in 2021. The increase is primarily attributable to the increase in share base compensation expenses.

 

Financing Expenses, Net. Financing income, net for the three months ended March 31, 2022 amounted to $3,296. Financing expenses, net for the three months ended March 31, 2021 amounted to $1,484. The increase is mainly due to currency exchange differences between the Dollar and the New Israeli Shekel.

 

Net Loss. Net loss for the three months ended March 31, 2022 was $1,636,796 and is primarily attributable to research and development and general and administrative expenses.

 

Financial Condition, Liquidity and Capital Resources

 

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. At March 31 and 2022 and 2021, we had current assets of $1,551,868 and $202,433 respectively, and total assets of $1,815,794 and $483,459 respectively. The increase in total assets is due to an increase in Prepaid share based payment to service providers balance offset by decrease in right of use asset arising from operating lease. We had current liabilities of $758,598 as compared to $592,050 as of March 31, 2022 and 2021, respectively and total liabilities of $3,087,605 as compared to $2,440,712 as of March 31, 2022 and 2021, respectively. The increase is mainly attributed to the increase in the balance of employees and related institutions, accrued expenses, and increase in loans received from a related party offset by decrease in right of use liabilities arising from operating lease.

 

At March 31, 2022, we had a cash balance of $385,957 compared to the cash balance of $46,022 as of December 31, 2021. We have no cash equivalents.

 

At March 31, 2022, we had a working capital of $793,270 as compared with a working capital of $547,972 at December 31, 2021.

 

During March 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities in an aggregated amount of $500,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. In consideration thereof the holders are entitled to 5,000,000,000 shares of Common Stock and warrants for an additional 5,000,000,000 shares of Common Stock, of which to date 2,500,000,000 shares of Common Stock and warrants for an additional 2,500,000,000 shares of Common Stock have been issued.

 

We expect that our existing cash and cash equivalents as well as expected revenues will enable us to fund our operations and capital expenditure requirements through year end 2022. Our requirements for additional capital during this period will depend on many factors.

 

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

 

16
 

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. We have a stockholders’ deficit of $1,271,811 and a working capital of $793,270 at March 31, 2022 as well as negative operating cash flows. These conditions raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

Off-Balance Sheet Arrangements We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures.

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer, to allow timely decisions regarding required disclosure. Management, with the participation of our Interim Chief Executive Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2022. Based on that evaluation, our management, including our Interim Chief Executive Officer, concluded that our disclosure controls and procedures were not effective as of March 31, 2022.

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2021, our management concluded that our internal control over financial reporting was not effective at December 31, 2021. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The limitation of the Company’s internal control over financial reporting was due to the applied risk-based approach which is indicative of many small companies with limited number of staff in corporate functions. The identified weakness were:

 

Material Weakness – We did not maintain effective controls over certain aspects of the financial reporting process because we (i) lacked a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and (ii) we lacked controls over the disclosure of our business operations.
   
lack of segregation of duties Significant Deficiencies – Inadequate segregation of duties.

 

Our management believes the weaknesses identified above have not had any material effect on our financial results.

 

17
 

 

We expect to be materially dependent upon third parties to provide us with accounting consulting services for the foreseeable future which we believe will mitigate the impact of the material weaknesses discussed above. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP and establish an audit committee and implement internal controls and procedures, there are no assurances that the material weaknesses and significant deficiencies in our disclosure controls and procedures will not result in errors in our financial statements which could lead to a restatement of those financial statements.

 

Changes in Internal Controls over Financial Reporting.

 

Except for the material weakness and associated remediation plan, , there have been no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II—OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

On October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The suit relates to the Stock Purchase Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate. The Suit sought declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the FSC transaction that are still outstanding.

 

A hearing was set for January 6, 2021 whereupon mediation was ordered. Mediation meetings were held but no resolution was reached. The Florida lawsuit is currently pending.

 

On or about, January 19, 2022, EL filed a lawsuit in the Delaware Court of Chancery seeking to remove the restrictive legend from all the shares of Common Stock held by EL (the “2022 Lawsuit”), which are approximately 23,000,000,000 shares. The Company retained the services of Delaware counsel and has moved to dismiss or stay the 2022 Lawsuit in favor of the previously filed Florida lawsuit, which involves the same parties and same issues. The Company’s motion is currently pending in the Delaware Court of Chancery.

 

From time to time we may become involved in various legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings or claims that we believe, either individually or in the aggregate, will have a material adverse effect on our business, financial condition, or results of operations.

 

ITEM 1A. RISK FACTORS

 

An investment in the Company’s Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on April 14, 2022, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our Common Stock. There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

18
 

 

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

 

(i) During March 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities in an aggregated amount of $500,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. In consideration thereof the holders are entitled to 5,000,000,000 shares of Common Stock and warrants for an additional 5,000,000,000 shares of Common Stock, of which to date 2,500,000,000 shares of Common Stock and warrants for an additional 2,500,000,000 shares of Common Stock have been issued.

 

(ii) In February 2022, the Company awarded to a new advisory board appointee options under the Company’s 2021 Equity Incentive Plan to purchase 6,000,000,000  shares of the Company’s common stock, at a per share exercise price of $0.0001 per share, which the exercise price vest as follows: 25% (i.e., 1,500,000,000) option shares vest on the first anniversary of the appointment to the advisory board and the balance in increments of 400,000,000 shares on each subsequent three (3) month anniversary.

 

(iii) In January 2022, the Company awarded to a new advisory board appointee options under the Company’s 2021 Equity Incentive Plan to purchase 400,000,000 shares of the Company’s Common Stock. Options to purchase 100,000,000 shares of Common Stock are scheduled to vest on the first anniversary of the agreement and the remaining options vest quarterly, over additional 3 years.

 

We relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) by virtue of Section 4(a)(2) thereof and/or Regulation S promulgated by the SEC under the Act with respect to the issuance of such securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None.

 

ITEM 5. OTHER INFORMATION:

 

(ii) On May 15, 2022, the Company granted options under the 2021 Plan (2021) to directors, employees and service providers to purchase an aggregate of 34,900,000,000 shares of Common Stock exercisable at a per share exercise price of $0.0001. Of the options granted, 5,000,000,000 were issued to CEO. The options vest on an annual basis with 25% of the option grant vesting on each anniversary of the option grant. Following vesting the options are exercisable through the sixth month anniversary following the last instalment vesting date.

 

ITEM 6. EXHIBITS

 

Exhibit Index:

 

31.1*   Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
     
32.1*   Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

 

19
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

WORLD HEALTH ENERGY HOLDINGS, INC.  
(Registrant)  
     
By: /s/ Giora Rozensweig  
  Giora Rozensweig  
  Interim Chief Executive Officer  
  (Principal Executive Officer and Principal Financial and Accounting Officer)  
     
Date: May 17, 2022  

 

20

 

World Health Energy (PK) (USOTC:WHEN)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 World Health Energy (PK) 차트를 더 보려면 여기를 클릭.
World Health Energy (PK) (USOTC:WHEN)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 World Health Energy (PK) 차트를 더 보려면 여기를 클릭.